Discontinuing continuous glucose monitoring leads to the loss of approximately half of the additional time in glycemic range accrued during its use among people with type 2 diabetes, MOBILE study data show.
Insulin sensitivity may be associated with the likelihood of partial remission in children and adolescents newly diagnosed with type 1 diabetes, regardless of C-peptide levels and BMI, research suggests.
Flash glucose monitoring improves glycemic control and reduces diabetic ketoacidosis rates across nearly all age, sex, and sociodemographic strata, regardless of insulin pump use, according to UK observational data.
The addition of liraglutide rather than extra oral antidiabetic drugs may offer more sustained glycemic control for people with type 2 diabetes who have inadequate control with metformin, suggest findings of the international LIRA-PRIME study.
Both small and large nerve fiber impairment can be detected among people with well-controlled recent-onset type 1 or type 2 diabetes, and may regress with time, shows German research presented at the virtual 57th EASD Annual Meeting.
Data from Scotland show that low socioeconomic status increases people’s risk for developing type 2 diabetes, while for those with type 1 diabetes it increases time spent with complications and reduces life expectancy.
Children and adults with type 1 diabetes achieve significant reductions in glycated hemoglobin and hypoglycemic events during their first 90 days of using the Omnipod DASH insulin pump system, show real-world data.
Insulin-naïve people with type 2 diabetes initiating the second-generation basal insulins glargine 300 or degludec 100 experience similar improvements in glycated hemoglobin levels, show data from the real-world RESTORE-2 study.
Findings from the SoliMix trial indicate that iGlarLixi may improve glycemic control with weight benefit compared with BIAsp 30 among people with suboptimally controlled type 2 diabetes on basal insulin.